Scarica l'app Stockscreener
572.39
2.04%
11.46
Dopo l'orario di chiusura:
572.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$560.93
Aprire:
$574.37
Volume 24 ore:
461.05K
Relative Volume:
0.37
Capitalizzazione di mercato:
$60.76B
Reddito:
$14.09B
Utile/perdita netta:
$4.50B
Rapporto P/E:
14.57
EPS:
39.28
Flusso di cassa netto:
$2.96B
1 W Prestazione:
+4.46%
1M Prestazione:
+11.81%
6M Prestazione:
-17.60%
1 anno Prestazione:
-45.77%
Intervallo 1D:
$571.54
$575.22
Intervallo di 1 settimana:
$541.50
$575.22
Portata 52W:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Acquired Rep. Robert Bresnahan, Jr. - MarketBeat
Regeneron Pharmaceuticals' (REGN) Buy Rating Reaffirmed at Canaccord Genuity Group - MarketBeat
ANI Pharma stock drops on trial setback (ANIP:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Legato Capital Management LLC - MarketBeat
Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances - Yahoo Finance
Balentine LLC Invests $680,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Morse Asset Management Inc Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Massachusetts Financial Services Co. MA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron's Trading Volume Surges 40.54% to $546 Million Ranking 212th in Stock Market - AInvest
Metastatic Castration-Resistant Prostate Cancer Clinical - openPR.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Victory Capital Management Inc. - MarketBeat
Metastatic Castration-Resistant Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals - Barchart.com
Beacon Investment Advisory Services Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
M. Kulyk & Associates LLC Acquires 528 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lowered by Edgestream Partners L.P. - MarketBeat
Regeneron’s New Trial: A Game-Changer for Lung Cancer Treatment? - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Sells 21,337 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Y Intercept Hong Kong Ltd Has $6.16 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. Stock Analysis and ForecastExplosive trading growth - jammulinksnews.com
Los Angeles Capital Management LLC Has $4.93 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What drives Regeneron Pharmaceuticals Inc. stock priceOutstanding capital appreciation - jammulinksnews.com
Evergreen Wealth Management LLC Invests $3.59 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Neutralizing Antibody Market Surges with Monoclonal Therapy & - openPR.com
South Dakota Investment Council Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Private Advisor Group LLC Has $9.05 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What analysts say about Regeneron Pharmaceuticals Inc. stockSuperior trading gains - printweek.in
Is Regeneron Pharmaceuticals Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com
678 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by AustralianSuper Pty Ltd - MarketBeat
Apollon Wealth Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish? - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sumitomo Life Insurance Co. - MarketBeat
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. - The Motley Fool
Cwm LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer? - TipRanks
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer? - TipRanks
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? - The Globe and Mail
Bailard Inc. Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet? - 富途牛牛
Wealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Las bolsas europeas suben, con el foco en los resultados - Yahoo Finanzas
Concord Asset Management LLC VA Purchases 972 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires Shares of 47,567 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.11%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):